# OnCo record idea-cost-low-dose-immunotherapy-trials (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-cost-low-dose-immunotherapy-trials/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-cost-low-dose-immunotherapy-trials" ;
  schema:name "Test one-tenth-dose immunotherapy where the full dose is unaffordable"@en ;
  schema:description "A randomised trial at Tata Memorial added nivolumab at 20 mg every three weeks, about one-twelfth of the standard dose, to cheap metronomic chemotherapy for head and neck cancer patients who could not afford full-dose immunotherapy, and they lived longer. Checkpoint inhibitors saturate their target far below approved doses, so publicly funded trials should test low doses in common cancers."@en ;
  schema:url <https://onco.cc/ideas/idea-cost-low-dose-immunotherapy-trials/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.22.01015> ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:institutions <https://onco.cc/institutions/tata-memorial/> ;
  onco:terms <https://onco.cc/terms/project-optimus/> ;
  onco:trials <https://onco.cc/trials/checkmate-141/>, <https://onco.cc/trials/keynote-048/>, <https://onco.cc/trials/keynote-412/>, <https://onco.cc/trials/keynote-689/>, <https://onco.cc/trials/nivopostop/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-048-lancet-2019/>, <https://onco.cc/key-papers/paper-jean-pascal-machiels-lancet-2019/>, <https://onco.cc/key-papers/paper-pembrolizumab-head-and-neck-j-clin-oncol-2017/> .